Rhino Propels Federated AI into the Enterprise Tech Stack Bavarian Nordic to Host Full Year 2022 Results Conference Call
COPENHAGEN, Denmark – February 24, 2023 – Bavarian Nordic A/S (OMX: BAVA) will publish its…
ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)
FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that…
Press release: New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme® (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease
New Phase 3 data presented at WORLDSymposium™ reinforce Nexviazyme®(avalglucosidase alfa) as potential new standard of…
Black Mountain Investment Group Announces Its Acquisition of Flight GPS, Expanding Its Aviation Portfolio
New York, New York–(Newsfile Corp. – February 24, 2023) – Black Mountain Investment Group (“Black…
BNBTIGER Launches as a Decentralized Community Experiment on Binance Smart Chain to Rebuild Market Trust and Eliminate Zeros
Norfolk, Nebraska–(Newsfile Corp. – February 24, 2023) – BNBTiger has officially launched, marking a new…
Evertz Technologies Limited to Announce Third Quarter 2023 Results on March 2, 2023
Burlington, Ontario–(Newsfile Corp. – February 24, 2023) – Evertz Technologies Limited (TSX: ET) will release…
Cisco and NTT Collaborate to Bring Private 5G to Enterprise Customers to Accelerate Industry Transformation
SAN JOSE, Calif. & LONDON–(BUSINESS WIRE)–Cisco, a worldwide leader in technology, and NTT Ltd., a…
Mind and Body Company Launches Flagship Product Line
Oola’s Mind and Body supplements bring balance and simplicity to your nutrition SALT LAKE CITY–(BUSINESS…
California Resources Corporation Initiates Strategic Realignment of Business Operations and Corporate Structure to Maximize Cash Flow Per Share
Francisco J. Leon to Succeed Mark A. McFarland as President and Chief Executive Officer McFarland…
Life Storage Publishes Investor Presentation Regarding Unsolicited Proposal from Public Storage
Conference Call at 8:00 a.m. Eastern Time Today to Review Presentation, Fourth Quarter and Full…
Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
FRIENDSWOOD, Texas–(BUSINESS WIRE)–$CSTL #CSTL–Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests…
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical…
GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP), a clinical…
SELLAS Life Sciences Announces Pricing of $20.0 Million Underwritten Public Offering
NEW YORK, Feb. 24, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (Nasdaq: SLS)…
Timber Pharmaceuticals Receives European Orphan Drug Designation for TMB-001 in X-Linked Recessive Ichthyosis
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France,…
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
CAMBRIDGE, Mass., Feb. 24, 2023 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage…
Frontier’s Record Quarter Accelerates Transformation to Growing Digital Infrastructure Company
Reports Fourth-Quarter and Full-Year 2022 Financial Results NORWALK, Conn.–(BUSINESS WIRE)–Frontier Communications Parent, Inc. (NASDAQ: FYBR)…
Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office
New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late…
Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023
NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO,…
Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy…